Ethan Oliver Bryson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ethan Oliver Bryson has a total of 302 co-authors. Here are the top co-authors by number of shared publications:
- Charles H. Kellner
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
21 shared publications - Amy Starr Aloysi
Psychiatry
5 shared publications Mimi C. Briggs
5 shared publicationsRosa M. Pasculli
5 shared publicationsAmy S. Aloysi
3 shared publicationsElizabeth A M Frost
3 shared publications
Latest Publications
- 29 May 2024
- Published by Springer Nature
- p. 103-125
Elective Surgery for Patients with Substance Use Disorder or Recent Substance Misuse
- 29 May 2024
- Published by Springer Nature
- p. 103-125
Elective Surgery for Patients with Substance Use Disorder or Recent Substance Misuse
- 22 July 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (12) , 5359-5360
Do Ask, Do Tell: Optimizing Anesthesia for Elective Procedures in Patients with Recent Illicit Drug Use
- 22 July 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (12) , 5359-5360
Do Ask, Do Tell: Optimizing Anesthesia for Elective Procedures in Patients with Recent Illicit Drug Use
- 1 April 2020
- Published by Elsevier in BJA Education
- Vol. 20 (4) , 114-119
Emerging worldwide trends in substances diverted for personal non-medical use by anaesthetists
- 1 April 2020
- Published by Elsevier in BJA Education
- Vol. 20 (4) , 114-119
Emerging worldwide trends in substances diverted for personal non-medical use by anaesthetists
- 19 November 2019
- Published by Wolters Kluwer Health in International Anesthesiology Clinics
- Vol. 58 (1) , 45-49
The impact of chemical dependency on health care professionals involved with the delivery of anesthesia
- 19 November 2019
- Published by Wolters Kluwer Health in International Anesthesiology Clinics
- Vol. 58 (1) , 45-49
The impact of chemical dependency on health care professionals involved with the delivery of anesthesia
- 5 March 2018
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 26 (4) , 391-393
Extreme variability in succinylcholine dose for muscle relaxation in electroconvulsive therapy
Objectives: To determine what dose of succinylcholine falls outside the range of 2 SD above or below the mean optimal dose of 0.9 mg/kg used for electroconvulsive therapy (ECT). Methods: In this retrospective chart review, for all patients who received ECT at our institution within the 5-year study period, the initial dose of succinylcholine in milligrams per kilogram was compared with subsequent doses after adjustments were made for individual patient responses. Mean and SD were calculated using the dose of succinylcholine, once the optimal dose for each patient had been determined, based on clinical response. Results: Five hundred patients treated during the 5-year period met inclusion criteria, 180 (36%) of whom required an adjustment of the succinylcholine dosing either above (119 patients) or below (61 patients) the 0.9 mg/kg standard after their first treatment. Conclusions: In those patients who required an adjustment of 2 SD either above or below the mean dose of succinylcholine (29 patients, 5.8%), adequate neuromuscular blockade was only achieved with either an increased dose of up to 2.10 mg/kg or a decreased dose as low as 0.29 mg/kg.
- 5 March 2018
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 26 (4) , 391-393
Extreme variability in succinylcholine dose for muscle relaxation in electroconvulsive therapy
Objectives: To determine what dose of succinylcholine falls outside the range of 2 SD above or below the mean optimal dose of 0.9 mg/kg used for electroconvulsive therapy (ECT). Methods: In this retrospective chart review, for all patients who received ECT at our institution within the 5-year study period, the initial dose of succinylcholine in milligrams per kilogram was compared with subsequent doses after adjustments were made for individual patient responses. Mean and SD were calculated using the dose of succinylcholine, once the optimal dose for each patient had been determined, based on clinical response. Results: Five hundred patients treated during the 5-year period met inclusion criteria, 180 (36%) of whom required an adjustment of the succinylcholine dosing either above (119 patients) or below (61 patients) the 0.9 mg/kg standard after their first treatment. Conclusions: In those patients who required an adjustment of 2 SD either above or below the mean dose of succinylcholine (29 patients, 5.8%), adequate neuromuscular blockade was only achieved with either an increased dose of up to 2.10 mg/kg or a decreased dose as low as 0.29 mg/kg.
- 1 April 2017
- Published by Elsevier in Revista de Psiquiatría y Salud Mental
- Vol. 10 (2) , 126-127
¿Debería desempeñar un papel la mascarilla laríngea en la terapia electroconvulsiva?
- 1 April 2017
- Published by Elsevier in Revista de Psiquiatría y Salud Mental
- Vol. 10 (2) , 126-127
¿Debería desempeñar un papel la mascarilla laríngea en la terapia electroconvulsiva?
- 7 December 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (2) , 219-235
The impaired anesthesiologist: what you should know about substance abuse
Despite our considerable experience with the problem of addiction in our specialty, most anesthesia care providers don’t know how to identify or help an impaired colleague. The purpose of this article to provide sufficient information on substance use disorder (SUD) to aid in its identification amongst colleagues and to assist in its management. Depending on the region, 10-15% of the general population is prone to developing a SUD and will abuse drugs or alcohol at some point in their life. Physicians and other healthcare professionals are not immune to the disease of addiction and are just as prone to developing SUD as laypersons. Even so, the risk of mortality is significantly increased because of access to potent and highly addictive anesthetic agents with a narrow therapeutic index when self-administered. Also, the number of anesthesia residents who are identified as having SUD is currently increasing. Due to the considerable morbidity and mortality associated with the abuse of anesthetic agents as well as the continuous increase in the rate of substance abuse by anesthesia providers, it is essential for anesthesia care providers to become familiar with the presenting signs and symptoms of substance abuse and impairment.
- 7 December 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (2) , 219-235
The impaired anesthesiologist: what you should know about substance abuse
Despite our considerable experience with the problem of addiction in our specialty, most anesthesia care providers don’t know how to identify or help an impaired colleague. The purpose of this article to provide sufficient information on substance use disorder (SUD) to aid in its identification amongst colleagues and to assist in its management. Depending on the region, 10-15% of the general population is prone to developing a SUD and will abuse drugs or alcohol at some point in their life. Physicians and other healthcare professionals are not immune to the disease of addiction and are just as prone to developing SUD as laypersons. Even so, the risk of mortality is significantly increased because of access to potent and highly addictive anesthetic agents with a narrow therapeutic index when self-administered. Also, the number of anesthesia residents who are identified as having SUD is currently increasing. Due to the considerable morbidity and mortality associated with the abuse of anesthetic agents as well as the continuous increase in the rate of substance abuse by anesthesia providers, it is essential for anesthesia care providers to become familiar with the presenting signs and symptoms of substance abuse and impairment.
- 12 November 2016
- Published by Springer Nature
- p. 33-34
Does Electrophysiology Really Have to Reprogram My Patient’s Pacemaker Prior to Electroconvulsive Therapy?
- 12 November 2016
- Published by Springer Nature
- p. 33-34
Does Electrophysiology Really Have to Reprogram My Patient’s Pacemaker Prior to Electroconvulsive Therapy?
- 1 September 2016
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 32 (3) , 204-206
General Anesthesia in a Patient With Urticaria Pigmentosa Referred for Electroconvulsive Therapy
Urticaria pigmentosa is a rare disorder characterized by an abnormal systemic proliferation of mast cells. In this condition, various triggers can induce either cutaneous histamine release, resulting in rash, or generalized histamine release, resulting in symptomatic hypotension, syncope, or in its severest form, an anaphylactoid reaction resistant to most resuscitative measures. Many anesthetic agents and adjuncts are known potential triggers, and patients who require surgery or procedures under anesthesia must be managed carefully. In this review, we describe the safe use of general anesthesia for electroconvulsive therapy in a patient with urticaria pigmentosa and discuss the association between psychiatric disorders and mastocytoses.
- 1 September 2016
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 32 (3) , 204-206
General Anesthesia in a Patient With Urticaria Pigmentosa Referred for Electroconvulsive Therapy
Urticaria pigmentosa is a rare disorder characterized by an abnormal systemic proliferation of mast cells. In this condition, various triggers can induce either cutaneous histamine release, resulting in rash, or generalized histamine release, resulting in symptomatic hypotension, syncope, or in its severest form, an anaphylactoid reaction resistant to most resuscitative measures. Many anesthetic agents and adjuncts are known potential triggers, and patients who require surgery or procedures under anesthesia must be managed carefully. In this review, we describe the safe use of general anesthesia for electroconvulsive therapy in a patient with urticaria pigmentosa and discuss the association between psychiatric disorders and mastocytoses.
- 1 May 2016
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 30, 24-32
Preventable drug waste among anesthesia providers: opportunities for efficiency
- 1 May 2016
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 30, 24-32
Preventable drug waste among anesthesia providers: opportunities for efficiency